Journal ArticleDOI
Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors.
TLDR
A new case of pembrolizumab-induced MG is presented and insights are provided into the underlying mechanisms of action of this phenomenon, which emphasises the importance of early recognition and robust treatment of this toxicity.About:
This article is published in European Journal of Cancer.The article was published on 2017-09-01. It has received 205 citations till now. The article focuses on the topics: Immune checkpoint & Pembrolizumab.read more
Citations
More filters
Journal ArticleDOI
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Filipe Martins,Filipe Martins,Latifyan Sofiya,Gerasimos P. Sykiotis,Faiza Lamine,Michel H. Maillard,Montserrat Fraga,Keyvan Shabafrouz,Camillo Ribi,Anne Cairoli,Yan Guex-Crosier,Thierry Kuntzer,Olivier Michielin,Solange Peters,Georges Coukos,Georges Coukos,François Spertini,John A. Thompson,Michel Obeid,Michel Obeid +19 more
TL;DR: The epidemiology, treatment and management of the various immune-related adverse events that can occur in patients receiving immune-checkpoint inhibitors are described.
Journal ArticleDOI
Immune-related adverse events of checkpoint inhibitors.
Manuel Ramos-Casals,Julie R. Brahmer,Margaret K. Callahan,Margaret K. Callahan,Alejandra Flores-Chávez,Niamh M. Keegan,Munther A. Khamashta,Olivier Lambotte,Xavier Mariette,Aleix Prat,Maria E. Suarez-Almazor +10 more
TL;DR: This Primer by Ramos-Casals and colleagues summarizes the epidemiology, mechanisms, diagnosis and treatment of immune-related adverse events and should be prescribed carefully to reduce the potential of short-term and long-term complications.
Journal ArticleDOI
Management of Immunotherapy-Related Toxicities, Version 1.2019.
John A. Thompson,Bryan J. Schneider,Julie R. Brahmer,Stephanie Andrews,Philippe Armand,Shailender Bhatia,Lihua E. Budde,Luciano J. Costa,Marianne Davies,David Dunnington,Marc S. Ernstoff,Matthew J. Frigault,Brianna Hoffner,Christopher J. Hoimes,Mario E. Lacouture,Frederick L. Locke,Matthew A. Lunning,Nisha Mohindra,Jarushka Naidoo,Anthony J. Olszanski,Olalekan O. Oluwole,Sandip Pravin Patel,Sunil Reddy,Mabel Ryder,Bianca Santomasso,Scott Shofer,Jeffrey A. Sosman,Momen M. Wahidi,Yinghong Wang,Alyse Johnson-Chilla,Jillian L. Scavone +30 more
TL;DR: The content featured in this issue is an excerpt of the recommendations for managing toxicity related to immune checkpoint blockade and a review of existing evidence.
Journal Article
International consensus guidance for the management of myasthenia gravis
Donald B. Sanders,Janice M. Massey,Gil I. Wolfe,Michael Benatar,Amelia Evoli,Nils Erik Gilhus,Isabel Illa,Nancy L. Kuntz,Arthur Melms,Hiroyuki Murai,Michael W. Nicolle,Jacqueline Palace,David P. Richman,Jan J.G.M. Verschuuren,Pushpa Narayanaswami +14 more
Journal ArticleDOI
Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer
Mehdi Touat,Thierry Maisonobe,Samuel Knauss,Omar Ben Hadj Salem,Baptiste Hervier,Karine Auré,Tali-Anne Szwebel,Nora Kramkimel,Claire Lethrosne,Jean-Frédéric Bruch,Pauline Laly,Jacques Cadranel,Nicolas Weiss,Anthony Behin,Yves Allenbach,Olivier Benveniste,Timothée Lenglet,Dimitri Psimaras,Werner Stenzel,Sarah Leonard-Louis +19 more
TL;DR: IrMyositis presents with remarkably homogeneous and unique clinicopathologic features, expanding the nosologic spectrum of inflammatory myopathies in patients with cancer, and ICI withdrawal and treatment with corticosteroids improve outcome.
References
More filters
Journal ArticleDOI
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer,Scott S. Tykodi,Scott S. Tykodi,Laura Q.M. Chow,Wen-Jen Hwu,Suzanne L. Topalian,Patrick Hwu,Charles G. Drake,Luis H. Camacho,John S. Kauh,Kunle Odunsi,Henry C. Pitot,Omid Hamid,Shailender Bhatia,Renato G. Martins,Keith D. Eaton,Shuming Chen,Theresa M. Salay,Suresh Alaparthy,Joseph F. Grosso,Alan J. Korman,Susan M. Parker,Shruti Agrawal,Stacie M. Goldberg,Drew M. Pardoll,Ashok Kumar Gupta,Jon M. Wigginton +26 more
TL;DR: Antibody-mediated blockade of PD-L1 induced durable tumor regression and prolonged stabilization of disease in patients with advanced cancers, including non-small-cell lung cancer, melanoma, and renal-cell cancer.
Journal ArticleDOI
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Paul Waterhouse,Josef M. Penninger,Emma Timms,Andrew Wakeham,Arda Shahinian,Kelvin P. Lee,Craig B. Thompson,Henrik Griesser,Tak W. Mak +8 more
TL;DR: Although CTLA-4-deficient T cells proliferated spontaneously and strongly when stimulated through the T cell receptor, they were sensitive to cell death induced by cross-linking of the Fas receptor and by gamma irradiation, and is vital for the control of lymphocyte homeostasis.
Journal ArticleDOI
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
H Ueda,Howson Jmm.,Laura Esposito,Joanne M. Heward,Hywel Snook,Giselle Chamberlain,Dan Rainbow,Hunter Kmd.,Anne Smith,G Di Genova,G Di Genova,Mathias H. Herr,Mathias H. Herr,Ingrid Dahlman,Ingrid Dahlman,F Payne,Deborah J. Smyth,Christopher E. Lowe,Twells Rcj.,Sarah Howlett,Barry C. Healy,Sarah Nutland,Helen E. Rance,Vincent H. Everett,Luc J. Smink,A C Lam,Heather J. Cordell,Neil Walker,C Bordin,John S. Hulme,Costantino Motzo,Francesco Cucca,J F Hess,Michael L. Metzker,Michael L. Metzker,Jane Rogers,Simon G. Gregory,Amit Allahabadia,Amit Allahabadia,R Nithiyananthan,Eva Tuomilehto-Wolf,Jaakko Tuomilehto,Polly J. Bingley,Kathleen M Gillespie,Dag E. Undlien,Kjersti S. Rønningen,Cristian Guja,Constantin Ionescu-Tirgoviste,David A. Savage,Alexander P. Maxwell,Dennis Carson,Christopher Patterson,Jayne A. Franklyn,David Clayton,Laurence B. Peterson,Linda S. Wicker,John A. Todd,Gough Scl. +57 more
TL;DR: In this article, the authors identify polymorphisms of the cytotoxic T lymphocyte antigen 4 gene (CTLA4) as candidates for primary determinants of risk of the common autoimmune disorders Graves' disease, autoimmune hypothyroidism and type 1 diabetes.
Journal ArticleDOI
Antibody to acetylcholine receptor in myasthenia gravis Prevalence, clinical correlates, and diagnostic value
TL;DR: Assay of antireceptor antibody should prove a useful test in the diagnosis of myasthenia gravis, and presence or titer of antibody did not appear to correlate with age, sex, steroid therapy, or duration of symptoms.
Journal ArticleDOI
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott J. Antonia,Jose A. Lopez-Martin,Johanna C. Bendell,Patrick A. Ott,Matthew H. Taylor,Joseph Paul Eder,Dirk Jäger,M. Catherine Pietanza,Dung T. Le,Filippo de Braud,Michael A. Morse,Paolo A. Ascierto,Leora Horn,Asim Amin,Rathi N. Pillai,Jeffry Evans,Ian Chau,Petri Bono,Akin Atmaca,Padmanee Sharma,Christopher T. Harbison,Chen Sheng Lin,Olaf Christensen,Emiliano Calvo +23 more
TL;DR: An objective response was achieved in ten (10%) of 98 patients receiving nivolumab 3 mg/kg, one (33%) of three patients receivingnivolUMab 1mg/kg plus ipilimumab 1 mg /kg, and 14 (23%) of 61 receiving n ivolumAB 1 mg/ kg plus ipILimumab 3mg/ kg, and ten (19%) of 54 receiving nvolum ab 3 mg / kg plusipilimum
Related Papers (5)
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.
Lisa Zimmer,Simone M. Goldinger,Lars Hofmann,Carmen Loquai,Selma Ugurel,Ioannis Thomas,Maria I. Schmidgen,Ralf Gutzmer,Jochen Utikal,Daniela Göppner,Jessica C. Hassel,Friedegund Meier,Julia K. Tietze,Andrea Forschner,Carsten Weishaupt,Martin Leverkus,Renate Ursula Wahl,Ursula Dietrich,Claus Garbe,Michael C. Kirchberger,Thomas Eigentler,Carola Berking,Anja Gesierich,Angela M. Krackhardt,Dirk Schadendorf,Gerold Schuler,Reinhard Dummer,Lucie Heinzerling +27 more
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer,Christina Lacchetti,Bryan J. Schneider,Michael B. Atkins,Kelly J. Brassil,Jeffrey M. Caterino,Ian Chau,Marc S. Ernstoff,Jennifer M. Gardner,Pamela K. Ginex,Sigrun Hallmeyer,Jennifer Holter Chakrabarty,Natasha B. Leighl,Jennifer S. Mammen,David F. McDermott,Aung Naing,Loretta J. Nastoupil,Tanyanika Phillips,Laura Diane Porter,Igor Puzanov,Cristina A. Reichner,Bianca Santomasso,Carole Seigel,Alexander Spira,Maria E. Suarez-Almazor,Yinghong Wang,Jeffrey S. Weber,Jeffrey S. Weber,Jedd D. Wolchok,John A. Thompson +29 more
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin,Vanna Chiarion-Sileni,Rene Gonzalez,Jean-Jacques Grob,C. Lance Cowey,Christopher D. Lao,Dirk Schadendorf,Reinhard Dummer,Michael Smylie,Piotr Rutkowski,Pier Francesco Ferrucci,A. Hill,John Wagstaff,Matteo S. Carlino,John B A G Haanen,Michele Maio,Ivan Marquez-Rodas,Grant A. McArthur,Paolo A. Ascierto,Georgina V. Long,Margaret K. Callahan,Michael A. Postow,Michael A. Postow,Kenneth F. Grossmann,Mario Sznol,Brigitte Dréno,Lars Bastholt,Arvin Yang,Linda Rollin,Christine Horak,F. Stephen Hodi,Jedd D. Wolchok,Jedd D. Wolchok +32 more
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Douglas B. Johnson,Justin M. Balko,Margaret L. Compton,Spyridon Chalkias,Joshua M. Gorham,Yaomin Xu,Mellissa Hicks,Igor Puzanov,Matthew R Alexander,Tyler L. Bloomer,Jason R Becker,David Slosky,Elizabeth J. Phillips,Mark A. Pilkinton,Laura Deeanne Craig-Owens,Nina Kola,Gregory E. Plautz,Daniel Reshef,Jonathan S. Deutsch,Raquel P. Deering,Benjamin A. Olenchock,Andrew H. Lichtman,Dan M. Roden,Christine E. Seidman,Christine E. Seidman,Igor J. Koralnik,Jonathan G. Seidman,Robert D. Hoffman,Janis M. Taube,Luis A. Diaz,Robert A. Anders,Jeffrey A. Sosman,Javid Moslehi +32 more